Global Genomic and Proteomic Analysis Identified Critical Pathways Modulated by Proto-Oncogene PELP1 in TNBC.
DIA-MS
PELP1
RNA-seq
ribosome biogenesis
triple negative breast cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Feb 2022
13 Feb 2022
Historique:
received:
29
12
2021
revised:
09
02
2022
accepted:
11
02
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
The PELP1 oncogene is commonly overexpressed in many cancers, including triple negative breast cancer (TNBC). However, the mechanisms by which PELP1 contributes to TNBC progression are not well understood. To elucidate these mechanisms, we generated CRISPR-Cas9 mediated PELP1 knockout TNBC cell lines, and alterations in the proteome were examined using global data-independent acquisition mass spectrometry (DIA-MS). Further mechanistic studies utilized shRNA knockdown, Western blotting, and RNA-seq approaches. TCGA data sets were utilized for determining the status of PELP1 in TNBC patient tumors and for examining its correlation with ribosomal proteins. Global DIA-MS studies revealed that 127 proteins are upregulated while 220 proteins are downregulated upon PELP1-KO. Bioinformatic analyses suggested that the oncogenic activities of PELP1 involve regulation of expression of ribosomal proteins and ribosomal complexes. RNA-seq studies further suggested PELP1 modulates the functions of transcription factor c-Myc in TNBC. TCGA data confirmed PELP1 has high expression in TNBC patient tumors, and this high expression pattern correlates with c-Myc, a regulator of ribosomal proteins. Collectively, our global approach studies suggest that PELP1 contributes to TNBC progression by modulation of cell cycle, apoptosis, and ribosome biogenesis pathways.
Identifiants
pubmed: 35205680
pii: cancers14040930
doi: 10.3390/cancers14040930
pmc: PMC8924758
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : VA grant
ID : I01BX004545
Organisme : BLRD VA
ID : I01 BX004545
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA054174
Pays : United States
Organisme : NCI NIH HHS
ID : F31 CA257298
Pays : United States
Organisme : National Institute of Health
ID : 1F31CA257298
Références
Cancer Res. 2005 Jul 1;65(13):5571-7
pubmed: 15994929
Mol Oncol. 2021 Apr;15(4):1146-1161
pubmed: 33269540
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Sci Data. 2014 Sep 16;1:140031
pubmed: 25977788
Am J Pathol. 2008 Aug;173(2):301-10
pubmed: 18583314
Mol Biol Cell. 2021 Oct 1;32(20):ar3
pubmed: 34319761
Nat Commun. 2018 Dec 3;9(1):5128
pubmed: 30510204
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Nature. 2012 May 02;485(7396):109-13
pubmed: 22552098
Breast Cancer Res. 2019 Dec 26;21(1):150
pubmed: 31878959
PLoS One. 2011;6(6):e21095
pubmed: 21695158
Cancer Res. 2016 Mar 15;76(6):1653-63
pubmed: 26825173
Genome Biol. 2014;15(12):550
pubmed: 25516281
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Nat Rev Clin Oncol. 2010 Dec;7(12):683-92
pubmed: 20877296
Clin Cancer Res. 2011 Apr 15;17(8):2250-9
pubmed: 21421858
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Cancer Res. 2007 Jun 1;67(11):5505-12
pubmed: 17545633
Front Cell Dev Biol. 2021 Aug 23;9:716730
pubmed: 34497807
J Biol Chem. 2001 Oct 12;276(41):38272-9
pubmed: 11481323
BMC Cancer. 2015 Oct 15;15:699
pubmed: 26472563
Cancer Res. 2010 May 15;70(10):4024-33
pubmed: 20442285
Breast Cancer Res Treat. 2010 Apr;120(3):603-12
pubmed: 19495959
Mol Endocrinol. 2012 Apr;26(4):550-61
pubmed: 22403175
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Cancer Discov. 2017 Oct;7(10):1069-1087
pubmed: 28923911
Nature. 2008 Dec 18;456(7224):971-5
pubmed: 19011615
Database (Oxford). 2013 Jan 15;2013:bas060
pubmed: 23325629
Mol Cancer Res. 2012 Jan;10(1):25-33
pubmed: 22086908
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Hum Pathol. 2005 Jun;36(6):670-5
pubmed: 16021574
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Mol Biol Cell. 2012 Feb;23(4):716-28
pubmed: 22190735
Nucleus. 2011 Nov-Dec;2(6):527-32
pubmed: 22064470
Cancer Res. 2010 Sep 15;70(18):7166-75
pubmed: 20807815
J Clin Endocrinol Metab. 2004 Dec;89(12):6130-8
pubmed: 15579769
Biomed Pharmacother. 2015 Jul;73:97-101
pubmed: 26211588
Mol Carcinog. 2020 Mar;59(3):281-292
pubmed: 31872914
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Comput Struct Biotechnol J. 2021 Jul 18;19:4101-4109
pubmed: 34527184
Mol Cell. 2016 Nov 3;64(3):607-615
pubmed: 27814492
Mol Endocrinol. 2015 Sep;29(9):1222-9
pubmed: 26158753
Cancers (Basel). 2020 Apr 08;12(4):
pubmed: 32276534
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
PLoS Genet. 2008 Jun 06;4(6):e1000090
pubmed: 18535662
Oxid Med Cell Longev. 2014;2014:193523
pubmed: 24967003
Nat Rev Cancer. 2003 Mar;3(3):179-92
pubmed: 12612653
Breast Cancer Res Treat. 2015 Apr;150(3):487-99
pubmed: 25788226
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275